15 Aug 2025

T. Rowe Price: U.S. policy under Trump: What investors need to know

 From the Field By Timothy C. Murray, CFA®

We explore the policy changes that could matter the most for markets and asset allocation.

Key Insights
  • President Donald Trump’s second term is bringing significant changes in trade, tax and fiscal policy, and regulation.
  • These policy shifts could have important implications for markets, the economy, and specific industries in the U.S. and around the world.
  • In this dynamic environment, a top-down approach to asset allocation can be powerful when it’s combined with deep insights into individual companies.

The summer has brought more clarity on the specifics of trade and fiscal policy under President Donald Trump. Now investors must weigh the implications for inflation, the economy, and monetary policy.

Delays and rollbacks to the extreme “reciprocal tariffs” unveiled at the start of April—as well as trade agreements with key partners—have helped to anchor market expectations for the effective U.S. tariff rate. But the potential for tariffs targeting certain industries is a source of uncertainty.

The effective tariff rate for the U.S. is likely to end up somewhere between 10% and 20%—compared with roughly 2.5% at the start of 2025. Higher import duties and shifting supply chains should result in higher costs for companies, some of which will be passed through to customers via price increases.

What could this mean for the economy and markets? Inflation could accelerate, consumer spending could fall, and corporate profit margins could be squeezed. Small businesses, which account for more than 70% of U.S. employment, tend to have less pricing power and more sensitivity to the economy and interest rates. As such, they may face more pressure to lay off employees.

On the other hand, the tax and spending legislation that Congress passed in July should be modestly stimulative over the next few years. Here, the question is the extent to which more favorable tax treatment of capital expenditures and research and development will spur business investment. That said, stepped‑up spending on plants and equipment could lead to inflation in input costs.

The Federal Reserve must tread carefully as it walks the tightrope between keeping inflation in check with higher interest rates while being mindful of economic growth. Policymakers must also contend with political pressure to lower rates.

In this dynamic environment, a top-down understanding of the interplay between government policy, the economy, and the outlook for different asset classes can be especially powerful when it’s combined with deep insights into industries and individual companies in the U.S. and beyond.

The following table highlights some of the key policy areas we’re watching and the possible implications for asset allocation.

Policy considerations and investment playbook

Tariffs

What we're watching

  • So far, higher tariffs haven’t shown signs of being a major problem for the economy. Consumer and business confidence has also improved.
  • Higher tariffs are still likely to be inflationary, which could weigh on consumer spending, corporate profit margins, and economic growth.
  • Trump’s tariffs could put pressure on central banks to make the uneasy choice to cut interest rates despite the risk of higher inflation.
  • Rising geopolitical tensions also pose a risk.

Potential implications

  • (U.S. small-caps could face headwinds because they tend to hold more debt and lack pricing power, making them more sensitive to inflation, higher rates, and the economy.
  • () Concerns about a resurgence in inflation would warrant caution on intermediate- to longer‑duration1 assets.
  • (+) We see relative opportunity in international value and international small-caps, especially in regions where fiscal spending is increasing and where monetary policy is still dovish. European and UK equities look attractive in this regard.
  • (+) Equities linked to real assets, such as energy and metals, historically have acted as a hedge versus inflation. Near-term economic weakness would be a concern for oil and industrial metals.
  • (+) In fixed income, we prefer shorter-duration assets and short-term Treasury inflation protected securities (TIPS).

Tax and Fiscal Policy

What we're watching

  • Legislation passed in early July extended expiring tax cuts from the first Trump administration and included additional items that should provide a modest fiscal stimulus over the next few years.
  • Changes in tax treatment of business spending could lead to increased investment in plants, equipment, and research and development. This shift could add fuel to the spending boom on artificial intelligence.
  • The extent to which corporate tax benefits stimulate spending in other parts of the economy will be important to watch.
  • The prospect of increased borrowing costs from higher base interest rates and ongoing deficit spending is fueling concerns about the long-term sustainability of U.S. public debt.

Potential implications

  • () Increased issuance of U.S. Treasuries to finance deficit spending could lead to upward pressure on yields.
  • () Concerns about inflation and U.S. public debt levels make us skeptical of longer-duration U.S. Treasuries as a hedge against economic weakness.
  • (+U.S. value stocks could benefit from expansionary fiscal policy. However, slowing economic growth would be a headwind.
  • (+) In fixed income, we prefer shorter-duration assets and short-term TIPS.

Immigration

What we're watching

  • Stricter immigration policies could tighten the U.S. labor market, putting upward pressure on wages and prices later in 2025 and beyond.

Potential implications

  • (U.S. small-caps could face headwinds because they tend to hold more debt and lack pricing power, making them more sensitive to inflation, higher rates, and the economy.
  • () Concerns about a resurgence in inflation would warrant caution on intermediate- to longer‑duration assets.
  • (+) Equities linked to real assets, such as energy and metals, historically have acted as a hedge versus inflation. Still, near-term economic weakness is a concern for oil and industrial metals.
  • (+) In fixed income, we prefer shorter-duration assets and short-term TIPS.

Deregulation

What we're watching

  • Trump has continued efforts from his first term to reduce burdensome regulation, cutting the costs imposed on businesses.

Potential implications

  • (+) A more business-friendly regulatory environment could favor smaller companies and value stocks. Both would be sensitive to economic weakness.
  • (+) Leadership changes at key federal agencies could bring a lighter touch to regulation and supervision of the financials sector.2

Energy

What we're watching

  • Trump has pushed to reduce the regulatory burden on fossil fuels. Rolling back tighter emission rules and drilling restrictions advanced by the Biden administration are on the agenda. Permitting reform could also place more of an emphasis on fossil fuel-related infrastructure.
  • Tax and spending legislation passed in early July repealed tax credits for electric vehicles that were in the Inflation Reduction Act, a signature piece of legislation passed during Biden’s presidency.

Potential implications

  • (+) A more supportive regulatory environment could help the oil and gas industry at the margin. However, significant growth in domestic hydrocarbon production could be a challenge because of industry consolidation and a maturing resource base. Economic weakness would be a headwind.
  • () Companies in the electric vehicle supply chain could encounter demand headwinds. Utilities and renewable energy developers would also face uncertainties.

Health care

What we're watching

  • Fears surrounding potential policy headwinds could weigh on investor sentiment toward the sector.

Potential implications

  • () Potential cuts to Medicaid could be a headwind for managed care companies with more exposure to this market.
  • () The pharmaceutical industry could face challenges if the administration takes an aggressive approach to pricing negotiations for certain drugs under the Inflation Reduction Act. Tariffs also create uncertainty.
  • () Any funding cuts for agencies that give research grants and approve drugs represent headwinds for life science tools companies. Tariffs also create uncertainty.
  • () Rising interest rates historically have been a headwind for biotech stocks, especially earlier‑stage companies.
  • (+) Positive surprises on any of these fronts would serve as tailwinds.

Duration measures a bond’s sensitivity to changes in interest rates.

Gil Fortgang, an associate analyst who covers Washington and regulatory policy for T. Rowe Price Investment Management, explored this topic at length in “How the U.S. Election Could Impact the Financials Sector.”

Risks

Fixed‑income securities are subject to credit risk, liquidity risk, call risk, and interest‑rate risk. As interest rates rise, bond prices generally fall. Small‑cap stocks have generally been more volatile in price than the large‑cap stocks. Because of the cyclical nature of natural resource companies, their stock prices and rates of earnings growth may follow an irregular path. While U.S. government‑backed securities generally are considered to be among the highest credit quality, they are subject to market risk. The primary source of risk is the possibility of rising interest rates, which generally cause bond prices to fall. In periods of no or low inflation, other types of bonds, such as US Treasury bonds, may perform better than Treasury Inflation‑Protected SecuritiesFinancial services companies may be hurt when interest rates rise sharply and may be vulnerable to rapidly rising inflation. International investments can be riskier than U.S. investments due to the adverse effects of currency exchange rates, differences in market structure and liquidity, as well as specific country, regional, and economic developments. These risks are generally greater for investments in emerging markets. The value approach to investing carries the risk that the market will not recognize a security’s intrinsic value for a long time or that a stock judged to be undervalued may actually be appropriately priced. Health sciences firms are often dependent on government funding and regulation and are vulnerable to product liability lawsuits and competition from low‑cost generic product. All charts and tables are shown for illustrative purposes only.

Additional Disclosure

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Important Information

Outside of the United States, this is intended for investment professional use only. Not for further distribution.

This material is being furnished for informational and/or marketing purposes only and does not constitute an offer, recommendation, advice, or solicitation to sell or buy any security.

Prospective investors should seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services.

Past performance is not a guarantee or a reliable indicator of future results. All investments involve risk, including possible loss of principal.

Information presented has been obtained from sources believed to be reliable, however, we cannot guarantee the accuracy or completeness. The views contained herein are those of the author(s), are as of August 2025, are subject to change, and may differ from the views of other T. Rowe Price Group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

All charts and tables are shown for illustrative purposes only. Actual future outcomes may differ materially from any estimates or forward‑looking statements provided.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.

Australia—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. For Wholesale Clients only. 

Canada—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.’s investment management services are only available to non‑individual Accredited Investors and non‑individual Permitted Clients as defined under National Instrument 45‑106 and National Instrument 31‑103, respectively. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.  

EEA—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L‑1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only. 

New Zealand—Issued by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 28, Governor Phillip Tower, 1 Farrer Place, Sydney NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013. 

Switzerland—Issued in Switzerland by T. Rowe Price (Switzerland) GmbH, Talstrasse 65, 6th Floor, 8001 Zurich, Switzerland. For Qualified Investors only. 

UK—This material is issued and approved by T. Rowe Price International Ltd, Warwick Court, 5 Paternoster Square, London EC4M 7DX which is authorised and regulated by the UK Financial Conduct Authority. For Professional Clients only. 

USA—Issued in the USA by T. Rowe Price Investment Services, Inc., distributor and T. Rowe Price Associates, Inc., investment adviser, 1307 Point Street, Baltimore, MD 21231, which are regulated by the Financial Industry Regulatory Authority and the U.S. Securities and Exchange Commission, respectively.

© 2025 T. Rowe Price. All Rights Reserved. T. Rowe Price, INVEST WITH CONFIDENCE, the Bighorn Sheep design, and related indicators (see troweprice.com/ip) are trademarks of T. Rowe Price Group, Inc. All other trademarks are the property of their respective owners.


Share this article